These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 8751095)

  • 1. Tissue plasminogen activator as a biochemical adjuvant in vitrectomy for proliferative diabetic vitreoretinopathy.
    Hesse L; Chofflet J; Kroll P
    Ger J Ophthalmol; 1995 Nov; 4(6):323-7. PubMed ID: 8751095
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effect of tissue plasminogen activator on premacular hemorrhage.
    Chung J; Kim MH; Chung SM; Chang KY
    Ophthalmic Surg Lasers; 2001; 32(1):7-12. PubMed ID: 11195747
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Enzymatically induced posterior vitreous detachment in proliferative diabetic vitreoretinopathy].
    Hesse L; Kroll P
    Klin Monbl Augenheilkd; 1999 Feb; 214(2):84-9. PubMed ID: 10218200
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Vitreous hemorrhage after vitrectomy in diabetic retinopathy and tissue plasminogen activator].
    Asensio Sánchez VM; Pérez Flández FJ; Carlos Bejarano J; Fernández Concellón L
    Arch Soc Esp Oftalmol; 2002 Jan; 77(1):7-12. PubMed ID: 11813114
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Induction of posterior vitreous detachment in rabbits by intravitreal injection of tissue plasminogen activator following cryopexy.
    Hesse L; Nebeling B; Schroeder B; Heller G; Kroll P
    Exp Eye Res; 2000 Jan; 70(1):31-9. PubMed ID: 10644418
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vitreous concentrations of TPA and plasminogen activator inhibitor are associated with VEGF in proliferative diabetic vitreoretinopathy.
    Hattenbach LO; Allers A; Gümbel HO; Scharrer I; Koch FH
    Retina; 1999; 19(5):383-9. PubMed ID: 10546932
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Advantages and disadvantages of the circumferential retinal cryocoagulation before vitrectomy in proliferative diabetic vitreoretinopathy].
    Schulze S; Zaki N; Kroll P
    Klin Monbl Augenheilkd; 2007 Aug; 224(8):647-52. PubMed ID: 17717781
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Treatment of intraocular fibrin formation with tissue plasminogen activator after vitrectomy].
    Zhao P; Wang W
    Zhonghua Yan Ke Za Zhi; 1995 Jul; 31(4):255-8. PubMed ID: 8745515
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of pars plana vitrectomy for proliferative diabetic vitreoretinopathy on preexisting diabetic maculopathy.
    Hoerle S; Poestgens H; Schmidt J; Kroll P
    Graefes Arch Clin Exp Ophthalmol; 2002 Mar; 240(3):197-201. PubMed ID: 11935276
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Little effect of tissue plasminogen activator in subretinal surgery for acute hemorrhage in age-related macular degeneration.
    Hesse L; Meitinger D; Schmidt J
    Ger J Ophthalmol; 1996 Nov; 5(6):479-83. PubMed ID: 9479539
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Management of postvitrectomy diabetic vitreous hemorrhage with tissue plasminogen activator (t-PA) and volume homeostatic fluid-fluid exchanger.
    Wu WC; Chang SM; Chen JY; Chang CW
    J Ocul Pharmacol Ther; 2001 Aug; 17(4):363-71. PubMed ID: 11572467
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Using enzymes in the posterior eye segment. Current status and future possibilities].
    Hesse L
    Ophthalmologe; 2001 Dec; 98(12):1176-80. PubMed ID: 11799901
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ultrastructure of internal limiting membrane removed during plasmin-assisted vitrectomy from eyes with diabetic macular edema.
    Asami T; Terasaki H; Kachi S; Nakamura M; Yamamura K; Nabeshima T; Miyake Y
    Ophthalmology; 2004 Feb; 111(2):231-7. PubMed ID: 15019368
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical use of recombinant plasminogen activator for intraocular fibrinolysis.
    Koerner F; Boehnke M
    Ger J Ophthalmol; 1992; 1(5):354-60. PubMed ID: 1477641
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Management of proliferative diabetic retinopathy.
    Gündüz K; Bakri SJ
    Compr Ophthalmol Update; 2007; 8(5):245-56. PubMed ID: 18201511
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [The predictive value of a classification for proliferative diabetic vitreoretinopathy].
    Hesse L; Heller G; Kraushaar N; Wesp A; Schroeder B; Kroll P
    Klin Monbl Augenheilkd; 2002; 219(1-2):46-9. PubMed ID: 11932810
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pars plana lensectomy, pars plana vitrectomy, and silicone oil tamponade as initial management of cataract and combined traction/rhegmatogenous retinal detachment involving the macula associated with severe proliferative diabetic retinopathy.
    Douglas MJ; Scott IU; Flynn HW
    Ophthalmic Surg Lasers Imaging; 2003; 34(4):270-8. PubMed ID: 12875454
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Upregulation of RAGE and its ligands in proliferative retinal disease.
    Pachydaki SI; Tari SR; Lee SE; Ma W; Tseng JJ; Sosunov AA; Cataldergirmen G; Scarmeas N; Caspersen C; Chang S; Schiff WM; Schmidt AM; Barile GR
    Exp Eye Res; 2006 May; 82(5):807-15. PubMed ID: 16364297
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Thrombolytic therapy for central retinal vein occlusion: results of a pilot study.
    Elman MJ
    Trans Am Ophthalmol Soc; 1996; 94():471-504. PubMed ID: 8981710
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Triamcinolone-assisted pars plana vitrectomy improves the surgical procedures and decreases the postoperative blood-ocular barrier breakdown.
    Sakamoto T; Miyazaki M; Hisatomi T; Nakamura T; Ueno A; Itaya K; Ishibashi T
    Graefes Arch Clin Exp Ophthalmol; 2002 Jun; 240(6):423-9. PubMed ID: 12107507
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.